Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial
Vanderbilt University Medical Center
200 participants
Dec 13, 2023
OBSERVATIONAL
Conditions
Summary
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Eligibility
Inclusion Criteria5
- Adults aged 18 and older
- Diagnosed with AF before age 60
- Scheduled for catheter-based AF ablation (de-novo or repeat)
- Able to provide written, informed consent
- P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
Exclusion Criteria8
- Diagnosed with a genetic CM or arrhythmia syndrome prior to AF
- VUS in 'possibly pathogenic' subgroup (control group only)
- Pacemaker or ICD
- Previous PVC or VT ablation
- LVEF \<20%
- Prosthetic mitral or aortic valve
- Contraindication to heparin
- Prior myocardial infarction.
Interventions
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06647459